Type 2 Diabetes: What Does a 55% Complication Risk Mean?

What does the 55% diabetes risk estimate actually mean?

The CALOR observational research programme examined US patients newly diagnosed with type 2 diabetes between 2010 and 2024. Their average age at enrolment was 59. The findings were announced ahead of the EASD annual meeting beginning September 28. [EASD research announcement](https://www.miragenews.com/one-in-three-with-type-2-diabetes-face-serious-1750855/)

A combined endpoint counts someone who experiences at least one specified outcome; it does not mean that everyone develops all three. Nor does chronic kidney disease automatically mean dialysis. Interpreting the estimate requires examining disease definitions, follow-up and how much each outcome contributes. Observational research can describe patterns, but cannot establish that diabetes alone caused every event or determine which treatment would prevent it. Age, existing illness and treatment access also matter when applying a population estimate to an individual.

Why should diabetes care assess the heart and kidneys together?

The heart and kidneys depend on a shared network of blood vessels and fluid regulation. Persistently elevated glucose can injure those vessels, while high blood pressure increases the workload on the heart and damages the kidneys' filtering system. When damaged kidneys retain excess salt and water, blood pressure can rise further. This helps explain why clinicians assess cardiovascular and kidney health together. [NIDDK: Heart Disease and Kidney Disease](https://www.niddk.nih.gov/health-information/kidney-disease/heart-disease)

Early diabetic kidney disease often produces no noticeable symptoms. NIDDK recommends yearly kidney testing for people with type 2 diabetes. Assessment includes a blood test to estimate filtration and a urine test for albumin, a protein that can leak through damaged filters. These tests provide information that a glucose reading cannot. A person who feels well or has reached their glucose target still needs appropriate kidney monitoring. [NIDDK: Diabetic Kidney Disease](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease)

How can people with type 2 diabetes reduce these risks?

A comprehensive care plan addresses blood pressure, cholesterol, smoking, physical activity and nutrition alongside blood glucose. Targets should reflect the person's health, treatment tolerance and circumstances. Reviewing these factors at routine appointments helps turn an alarming headline into practical decisions: which measurements need attention, whether medicines are being taken consistently, and what support would make daily management easier. [NIDDK: Diabetes, Heart Disease, and Stroke](https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke)

For eligible people with type 2 diabetes and chronic kidney disease, KDIGO guidance recommends SGLT2 inhibitors, medicines supported by randomized trials showing kidney and heart benefits. ACE inhibitors or angiotensin receptor blockers also have an established role in diabetic kidney disease with increased urine albumin. Treatment selection depends on kidney function, blood pressure, potassium and other clinical factors. These recommendations come from a broader evidence base than the conference report, and do not mean every newly diagnosed patient needs the same prescription. [KDIGO Clinical Practice Guideline for Chronic Kidney Disease](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)